Leerink Partnrs Has Bearish Outlook for ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities research analysts at Leerink Partnrs lowered their FY2025 EPS estimates for shares of Eledon Pharmaceuticals in a report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($1.14) for the year, down from their prior forecast of ($1.02). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($1.38) EPS, FY2028 earnings at ($1.36) EPS and FY2029 earnings at ($0.67) EPS.

Separately, Guggenheim began coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 price objective for the company.

Eledon Pharmaceuticals Stock Performance

ELDN opened at $3.41 on Wednesday. Eledon Pharmaceuticals has a 1 year low of $1.52 and a 1 year high of $5.54. The company’s 50 day simple moving average is $4.13 and its 200 day simple moving average is $3.88. The stock has a market capitalization of $204.20 million, a PE ratio of -1.70 and a beta of 0.80.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its earnings results on Thursday, March 20th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same quarter in the previous year, the business earned ($1.00) EPS.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its stake in shares of Eledon Pharmaceuticals by 418.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after buying an additional 6,412 shares in the last quarter. Alpine Global Management LLC purchased a new position in Eledon Pharmaceuticals in the 4th quarter worth approximately $56,000. ADAR1 Capital Management LLC acquired a new stake in Eledon Pharmaceuticals in the fourth quarter valued at approximately $66,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eledon Pharmaceuticals during the fourth quarter valued at approximately $76,000. Finally, Virtu Financial LLC acquired a new position in shares of Eledon Pharmaceuticals during the fourth quarter worth $82,000. 56.77% of the stock is owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).